These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16045292)

  • 41. Modeling chemical interaction profiles: I. Spectral data-activity relationship and structure-activity relationship models for inhibitors and non-inhibitors of cytochrome P450 CYP3A4 and CYP2D6 isozymes.
    McPhail B; Tie Y; Hong H; Pearce BA; Schnackenberg LK; Ge W; Valerio LG; Fuscoe JC; Tong W; Buzatu DA; Wilkes JG; Fowler BA; Demchuk E; Beger RD
    Molecules; 2012 Mar; 17(3):3383-406. PubMed ID: 22421792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
    Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
    Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products.
    Appiah-Opong R; Commandeur JN; van Vugt-Lussenburg B; Vermeulen NP
    Toxicology; 2007 Jun; 235(1-2):83-91. PubMed ID: 17433521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
    Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
    Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
    Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
    Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
    Zhou SF; Zhou ZW; Yang LP; Cai JP
    Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic interactions with piperazine-based 'party pill' drugs.
    Antia U; Tingle MD; Russell BR
    J Pharm Pharmacol; 2009 Jul; 61(7):877-82. PubMed ID: 19589229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Construction of Metabolism Prediction Models for CYP450 3A4, 2D6, and 2C9 Based on Microsomal Metabolic Reaction System.
    He SB; Li MM; Zhang BX; Ye XT; Du RF; Wang Y; Qiao YJ
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative study of hops-containing products on human cytochrome P450-mediated metabolism.
    Foster BC; Arnason JT; Saleem A; Tam TW; Liu R; Mao J; Desjardins S
    J Agric Food Chem; 2011 May; 59(9):5159-63. PubMed ID: 21476568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity.
    Kimura Y; Ito H; Ohnishi R; Hatano T
    Food Chem Toxicol; 2010 Jan; 48(1):429-35. PubMed ID: 19883715
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In Vitro Inhibition of Human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by Grandisin.
    Habenschus MD; Moreira FL; Lopes NP; de Oliveira ARM
    Planta Med; 2017 May; 83(8):727-736. PubMed ID: 28073119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19.
    Kolukisaoglu Ü; Wendler C; Goerdes D; Diener A; Thurow K
    J Enzyme Inhib Med Chem; 2010 Dec; 25(6):876-86. PubMed ID: 20578979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
    Galetin A; Houston JB
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1220-9. PubMed ID: 16763093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6.
    Manga N; Duffy JC; Rowe PH; Cronin MT
    SAR QSAR Environ Res; 2005; 16(1-2):43-61. PubMed ID: 15844442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel application of 2D and 3D-similarity searches to identify substrates among cytochrome P450 2C9, 2D6, and 3A4.
    Freitas RF; Bauab RL; Montanari CA
    J Chem Inf Model; 2010 Jan; 50(1):97-109. PubMed ID: 20055489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
    Yamazaki H; Shimada T
    Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of drug-drug interaction for silymarin.
    Doehmer J; Tewes B; Klein KU; Gritzko K; Muschick H; Mengs U
    Toxicol In Vitro; 2008 Apr; 22(3):610-7. PubMed ID: 18249085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
    Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
    Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes.
    Eng H; Obach RS
    Drug Metab Dispos; 2016 Aug; 44(8):1217-28. PubMed ID: 27271369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.